CR20240489A - Agentes aglutinantes 5t4 y usos de los mismos - Google Patents

Agentes aglutinantes 5t4 y usos de los mismos

Info

Publication number
CR20240489A
CR20240489A CR20240489A CR20240489A CR20240489A CR 20240489 A CR20240489 A CR 20240489A CR 20240489 A CR20240489 A CR 20240489A CR 20240489 A CR20240489 A CR 20240489A CR 20240489 A CR20240489 A CR 20240489A
Authority
CR
Costa Rica
Prior art keywords
binding agents
antibodies
antibody
present disclosure
disclosure provides
Prior art date
Application number
CR20240489A
Other languages
English (en)
Spanish (es)
Inventor
Seema Kantak
Charles Kaplan
Bonnie Hammer
Jeffrey N Higaki
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CR20240489A publication Critical patent/CR20240489A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20240489A 2022-05-13 2023-05-10 Agentes aglutinantes 5t4 y usos de los mismos CR20240489A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263341944P 2022-05-13 2022-05-13
PCT/US2023/066819 WO2023220626A2 (en) 2022-05-13 2023-05-10 5t4 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
CR20240489A true CR20240489A (es) 2025-01-07

Family

ID=88731098

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240489A CR20240489A (es) 2022-05-13 2023-05-10 Agentes aglutinantes 5t4 y usos de los mismos

Country Status (16)

Country Link
US (1) US20250326858A1 (enExample)
EP (1) EP4522660A4 (enExample)
JP (1) JP2025518493A (enExample)
KR (1) KR20250024530A (enExample)
CN (2) CN120607619A (enExample)
AU (1) AU2023267764A1 (enExample)
CA (1) CA3252305A1 (enExample)
CL (2) CL2024003442A1 (enExample)
CO (1) CO2024015383A2 (enExample)
CR (1) CR20240489A (enExample)
DO (1) DOP2024000234A (enExample)
IL (1) IL316788A (enExample)
MX (1) MX2024013871A (enExample)
PE (1) PE20251275A1 (enExample)
TW (1) TW202400639A (enExample)
WO (1) WO2023220626A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180472A1 (zh) * 2024-02-28 2025-09-04 惠和生物技术(上海)有限公司 单克隆抗体分子及其用途
US20260008868A1 (en) * 2024-07-05 2026-01-08 Solve Therapeutics, Inc. 5t4-binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596295A (en) * 2006-03-10 2013-01-25 Wyeth Corp Anti-5T4 antibodies and uses thereof
CA2959694C (en) * 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
CN114025797A (zh) * 2019-05-31 2022-02-08 昆士兰医学研究所理事会 抗Gal9免疫抑制性结合分子

Also Published As

Publication number Publication date
EP4522660A2 (en) 2025-03-19
PE20251275A1 (es) 2025-05-14
WO2023220626A3 (en) 2023-12-14
IL316788A (en) 2025-01-01
CL2025002572A1 (es) 2025-10-03
CL2024003442A1 (es) 2025-02-28
WO2023220626A2 (en) 2023-11-16
KR20250024530A (ko) 2025-02-18
MX2024013871A (es) 2024-12-06
US20250326858A1 (en) 2025-10-23
AU2023267764A1 (en) 2024-11-21
CN119546643A (zh) 2025-02-28
CN120607619A (zh) 2025-09-09
DOP2024000234A (es) 2025-02-28
TW202400639A (zh) 2024-01-01
JP2025518493A (ja) 2025-06-17
EP4522660A4 (en) 2026-04-29
CA3252305A1 (en) 2023-11-16
CO2024015383A2 (es) 2025-02-04

Similar Documents

Publication Publication Date Title
MX2022010515A (es) Conjugacion mediada por transglutaminasa.
ECSP20014523A (es) Conjugado de anticuerpo monoclonal contra bcma-fármaco
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
CL2023003607A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
ECSP20034868A (es) Conjugados anticuerpo anti-cd40-fármaco
BR112021015477A2 (pt) Anticorpos anti-cd228 e conjugados anticorpo-fármaco
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
CL2019001740A1 (es) Novedoso conjugado de amanitina.
EA201791550A1 (ru) Димеры бензодиазепинов, их конъюгаты и способы их получения и применения
JOP20210323A1 (ar) ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
CO2024015383A2 (es) Agentes aglutinantes 5t4 y usos de los mismos
MX2022013768A (es) Conjugados anticuerpo-fármaco (adc) que comprenden un anticuerpo anti-trop-2, composiciones que comprenden dichos adc, así como métodos para fabricar y utilizar los mismos.
CO2024013569A2 (es) Moléculas de unión contra frα
SA523451582B1 (ar) Ccr8 الأجسام المضادة لـ
MA43773B1 (fr) Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
BR112021012631A2 (pt) Anticorpos anti-ctla4 e métodos de uso dos mesmos
MX2023012848A (es) Conjugados de anticuerpo-farmaco anti-c-met.
CL2024004076A1 (es) Receptores quiméricos de steap1 y métodos de uso de los mismos
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.